Evidence map›Paper›PMID 31460277›Full record

ArticleACS omega2019

Design, Synthesis, DNA/HSA Binding, and Cytotoxic Activity of Half-Sandwich Ru(II)-Arene Complexes Containing Triarylamine-Thiosemicarbazone Hybrids.

Mathiyan Muralisankar, Ramachandran Dheepika, Jebiti Haribabu, Chandrasekar Balachandran, Shin Aoki, Nattamai S P Bhuvanesh, Samuthira Nagarajan

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Mathiyan MuralisankarDepartment of Chemistry, Central University of Tamil Nadu, Thiruvarur 610005, India.
Ramachandran DheepikaDepartment of Chemistry, Central University of Tamil Nadu, Thiruvarur 610005, India.
Jebiti HaribabuDepartment of Chemistry, National Institute of Technology, Tiruchirappalli 620015, India.
Chandrasekar BalachandranFaculty of Pharmaceutical Sciences and Research Institute of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan.
Shin AokiFaculty of Pharmaceutical Sciences and Research Institute of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan.
Nattamai S P BhuvaneshDepartment of Chemistry, Texas A & M University, College Station, Texas 77842, United States.
Samuthira NagarajanDepartment of Chemistry, Central University of Tamil Nadu, Thiruvarur 610005, India.
Central University of Tamil Nadu · INTokyo University of Science · JPNational Institute of Technology Tiruchirappalli · INTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organoruthenium complexes are potent alternatives for platinum-based complexes because of their superior anticancer activity. In this investigation, a series of new Ru(II)-arene complexes with triarylamine-thiosemicarbazone hybrid ligands with higher anticancer activity than cisplatin are reported. The molecular structure of the ligands and complexes was confirmed spectroscopically and supported by single-crystal X-ray crystallography. These complexes adopted a three-leg piano stool geometry. All the Ru(II)-arene complexes were systematically investigated for their in vitro cytotoxicity against human cervical (HeLa S3), lung (A549) cancer, and human normal lung (IMR-90) cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Interestingly, a pyrrolidine-attached Ru(II)-benzene complex exhibited superior activity against cancer cells with low IC

Identifiers

PMID31460277
PMCPMC6682138
OpenAlexW2954095911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.